Bio-Rad's clinical diagnostics segment revenues were up approximately 2 percent year over year in the quarter to $379.0 million. On a currency-neutral basis, the segment grew 3 percent due to growth in diabetes, quality controls, autoimmune, and blood typing products, as well as growth in Asia and the Americas.
DxTerity Diagnostics has appointed Brett Swansiger as chief commercialization officer. Prior to DxTerity, Swansiger held multiple positions at MDxHealth, including VP of managed care and payor strategy. Before MDxHealth, he served as VP of managed care and Asia market access for Agendia. Prior to Agendia, Swansiger help multiple positions at Prometheus Laboratories.
Cofactor is a large, structured listing of people, places, and things. Here you can find the description of each topic.